NASDAQ:INGNInogen Stock Price, Forecast & News

Inogen's stock was trading at $40.61 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, INGN stock has decreased by 14.1% and is now trading at $34.90.
View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating and 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Inogen.

Inogen is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Inogen.

Inogen Inc (NASDAQ:INGN) posted its earnings results on Tuesday, August, 4th. The medical technology company reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.20. The medical technology company earned $71.70 million during the quarter, compared to the consensus estimate of $79.96 million. Inogen had a net margin of 1.96% and a return on equity of 2.68%. The business's quarterly revenue was down 29.1% compared to the same quarter last year. During the same period last year, the firm posted $0.45 EPS.
View Inogen's earnings history.

4 equities research analysts have issued 1-year price targets for Inogen's shares. Their forecasts range from $35.00 to $75.00. On average, they anticipate Inogen's share price to reach $51.67 in the next year. This suggests a possible upside of 48.0% from the stock's current price.
View analysts' price targets for Inogen.

News coverage about INGN stock has trended very positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Inogen earned a news sentiment score of 4.0 on InfoTrie's scale. They also gave news coverage about the medical technology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Inogen.

Some companies that are related to Inogen include Avanos Medical (AVNS), Establishment Labs (ESTA), Invacare (IVC), RTI Surgical (RTIX), Sientra (SIEN), Lakeland Industries (LAKE), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Histogenics (HSGX), Allied Healthcare Products (AHPI), Ocugen (OCGN), Rewalk Robotics (RWLK), Precision Therapeutics (POAI), Bionik Laboratories (BNKL) and NanoVibronix (NAOV).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), First Solar (FSLR), Netflix (NFLX), Intel (INTC) and Advanced Micro Devices (AMD).

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Inogen's stock is owned by many different institutional and retail investors. Top institutional investors include Riverbridge Partners LLC (1.19%), Principal Financial Group Inc. (0.64%), Assenagon Asset Management S.A. (0.37%), Hussman Strategic Advisors Inc. (0.23%), Swiss National Bank (0.19%) and UBS Group AG (0.18%). Company insiders that own Inogen stock include Brenton Taylor, Byron Myers, Heath Lukatch, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson and Raymond Huggenberger.
View institutional ownership trends for Inogen.

INGN stock was sold by a variety of institutional investors in the last quarter, including Beacon Investment Advisory Services Inc., Russell Investments Group Ltd., Chicago Capital LLC, Riverbridge Partners LLC, Texas Permanent School Fund, PNC Financial Services Group Inc., and Cardinal Capital Management.
View insider buying and selling activity for Inogen.

INGN stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Hussman Strategic Advisors Inc., UBS Group AG, WINTON GROUP Ltd, Exchange Traded Concepts LLC, Swiss National Bank, Envestnet Asset Management Inc., and SG Americas Securities LLC. Company insiders that have bought Inogen stock in the last two years include Heath Lukatch, and Loren L Mcfarland.
View insider buying and selling activity for Inogen.

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INGN stock can currently be purchased for approximately $34.90.

Inogen has a market capitalization of $770.24 million and generates $361.94 million in revenue each year. The medical technology company earns $20.95 million in net income (profit) each year or $1.07 on an earnings per share basis. Inogen employs 1,020 workers across the globe.

The official website for Inogen is www.inogen.com.

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]